Microcap Ledger Biomerica Inc $BMRA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Irvine, CA
- Fiscal year end
- May 31
- Shares outstanding
- 4,598,968 [10-K/A 2026-09-28]
What the company doesAI summary of filing
Biomerica develops, manufactures, and markets diagnostic test products and therapeutic products for detection and treatment of medical conditions, sold to clinical laboratories, physicians' offices, hospitals, and consumers through over-the-counter channels. The company generates revenue from product sales and contract development and manufacturing services. The company is in the revenue-generating stage but is not currently profitable, with net sales of $4.5 million in fiscal 2026, and management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative operating cash flows, and limited liquidity. [10-K 2026-08-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended May 2026 | $4.45M | −$3.77M | −$3.42M | $1.31M | [10-K 2026-08-31] |
| FY ended May 2025 | $5.31M | −$4.97M | −$3.84M | $2.40M | [10-K 2026-08-31] |
- Quarterly cash burn
- −$855.3K
- Cash runway Estimate
- ~4.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-14 | 20,366,005 | [10-Q 2025-04-14] |
| 2025-08-29 | 2,815,410 | [10-K 2025-08-29] |
| 2025-09-26 | 2,869,900 | [10-K/A 2025-09-26] |
| 2025-10-14 | 2,869,900 | [10-Q 2025-10-14] |
| 2026-01-14 | 3,020,067 | [10-Q 2026-01-14] |
| 2026-04-13 | 3,090,269 | [10-Q 2026-04-13] |
| 2026-08-31 | 4,588,968 | [10-K 2026-08-31] |
| 2026-09-28 | 4,598,968 | [10-K/A 2026-09-28] |
- Shelf registration
- S-3 filed 2026-09-24; declared effective 2026-10-07 [S-3 2026-09-24]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-11-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-11-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-26 | Moatazedi David | buy | 10,000 | $1.60 | [4 2026-08-27] |
| 2026-08-26 | Chin Eric | buy | 6,250 | $1.60 | [4 2026-08-27] |
| 2026-08-26 | Barbieri Allen | buy | 20,000 | $1.60 | [4 2026-08-27] |
| 2026-08-26 | Irani Zackary S. | buy | 31,250 | $1.60 | [4 2026-08-27] |
| 2026-08-20 | Gary M. Huff | buy | 31,250 | $1.60 | [4 2026-08-27] |
| 2025-12-12 | Chin Eric | grant | 22,500 | — | [4 2026-01-28] |
| 2025-12-12 | Lu Gary | grant | 40,000 | — | [4 2025-12-31] |
| 2025-12-12 | Irani Zackary S. | grant | 52,500 | — | [4 2025-12-31] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 10-K/A | Amended report |
| 2026-09-24 | S-3 | Registration statement |
| 2026-09-24 | S-3 | Registration statement |
| 2026-08-31 | 10-K | Annual report |
| 2026-08-28 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-26 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-06-04 | 8-K | Material agreement entered; New financial obligation |
| 2026-04-13 | 10-Q | Quarterly report |
| 2026-01-14 | 10-Q | Quarterly report |
| 2025-12-16 | 8-K | Shareholder vote results |
| 2025-10-20 | DEF 14A | Proxy statement |
| 2025-10-14 | 10-Q | Quarterly report |
Alerts for $BMRA
Email me when Biomerica Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.